Pharmaceutical Litigation Attorneys
In 2012, Novartis, a large pharmaceutical company, made the decision to voluntarily recall one if its drugs, Valturna. Made with two medications, aliskiren and valsartan, Valturna is a type of prescription medication used to treat high blood pressure. Originally approved by the U.S. Food & Drug Administration is 2009, Valturna has been linked with an increased risk of certain dangerous—and even deadly—health consequences.
Studies Point to Increased Risk of Health Complication When Taking Valturna
When Valturna was tested for its safety and effectiveness by an independent commission (after Valturna had already been put on the market), the study shed light on evidence that taking Valturna significantly increased a patient’s risk of:
- Stroke;
- Renal complications;
- Hyperkalemia; and
- Low blood pressure.
According to the study and an
April 2012 safety communication published by the FDA, the primary cause of the complications listed above is the ingredient aliskiren. Taking aliskiren can increase a patient’s risk of death.
Take Action Today
Because of the statute of limitations, which limits the amount of time that you have to file a claim after being harmed by a defective drug, it is imperative that you consult with a
pharmaceutical litigation attorney near you now. At Napoli Shkolnik, PLLC, our attorneys have offices in multiple states, and can help you no matter where you are located.
April 17, 2024
The short answer to this question is, if you were hit by an Uber, you sue Uber because of the respondeat superior rule. The long answer to this...
Read the Article
April 12, 2024
In a monumental stride towards addressing the nation’s PFAS water contamination crisis, Paul Napoli, along with the co-leads of the AFFF Multi-District Litigation, have achieved a groundbreaking $750...
Read the Article
April 11, 2024
When AI innovator OpenAI released ChatGPT in November of 2022, it sent shockwaves through the world, from tech leaders to academia. Quickly, stories surfaced of people using ChatGPT to “cheat,”...
Read the Article